Blog
DSIP: Research Overview
Delta sleep-inducing peptide (DSIP) is a nonapeptide first isolated from rabbit cerebral venous blood, studied in relation to sleep architecture and neuroendocrine regulation.
A double-blind study published in Neuropsychobiology (1992) examined intravenous DSIP in 16 human chronic insomniac patients using a matched-pairs, parallel-groups design against a glucose placebo; compared with placebo, DSIP administration was associated with higher sleep efficiency and shorter sleep latency in this model (PubMed).
A review by Schneider-Helmert and Schoenenberger synthesized prior animal findings together with five double-blind human studies involving single and repeated intravenous DSIP injections, psychophysiological testing, and polygraphic recordings; in humans, DSIP showed good compatibility when injected slowly, with effects on sleep induction reported to last up to 20 hours (PubMed).
For laboratory research use only — not for human consumption. This content is presented for educational and informational purposes and is not intended as medical advice, a treatment claim, or usage instruction.
